Michael J Borowitz
Overview
Explore the profile of Michael J Borowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
13037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cecchini M, Borowitz M, Glassy E, Gullapalli R, Hart S, Hassell L, et al.
Arch Pathol Lab Med
. 2024 Sep;
149(2):142-151.
PMID: 39343982
Context.—: Generative artificial intelligence (AI) technologies are rapidly transforming numerous fields, including pathology, and hold significant potential to revolutionize educational approaches. Objective.—: To explore the application of generative AI, particularly...
2.
Rabin K, Devidas M, Chen Z, Ji L, Kairalla J, Hitzler J, et al.
J Clin Oncol
. 2023 Oct;
42(2):218-227.
PMID: 37890117
Purpose: Patients with Down syndrome (DS) and B-ALL experience increased rates of relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on Children's Oncology Group trials...
3.
Wood B, Devidas M, Summers R, Chen Z, Asselin B, Rabin K, et al.
Blood
. 2023 Aug;
142(24):2069-2078.
PMID: 37556734
The early thymic precursor (ETP) immunophenotype was previously reported to confer poor outcome in T-cell acute lymphoblastic leukemia (T-ALL). Between 2009 and 2014, 1256 newly diagnosed children and young adults...
4.
Knollmann-Ritschel B, Huppmann A, Borowitz M, Conran R
Acad Pathol
. 2023 Jul;
10(3):100086.
PMID: 37496887
Pathology is a core component of medical school curricula because understanding the pathogenesis of the disease is foundational both for diagnostic efficiency and optimal use of ancillary resources in patient...
5.
Hunger S, Tran T, Saha V, Devidas M, Valsecchi M, Gastier-Foster J, et al.
Lancet Haematol
. 2023 Jul;
10(7):e510-e520.
PMID: 37407142
Background: The outcome of children with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia significantly improved with the combination of imatinib and intensive chemotherapy. We aimed to investigate the efficacy of dasatinib,...
6.
Jain T, Ware A, Dalton W, Pasca S, Tsai H, Gocke C, et al.
Leuk Res
. 2023 Jun;
131:107345.
PMID: 37354804
Identification of genomic signatures with consistent clinicopathological features in myelodysplastic/myeloproliferative neoplasm (MDS/MPN) is critical for improved diagnosis, elucidation of biology, inclusion in clinical trials, and development of therapies. We describe...
7.
Hogan L, Brown P, Ji L, Xu X, Devidas M, Bhatla T, et al.
J Clin Oncol
. 2023 May;
41(25):4118-4129.
PMID: 37257143
Purpose: Blinatumomab, a bispecific T-cell engager immunotherapy, is efficacious in relapsed/refractory B-cell ALL (B-ALL) and has a favorable toxicity profile. One aim of the Children's Oncology Group AALL1331 study was...
8.
Schore R, Angiolillo A, Kairalla J, Devidas M, Rabin K, Zweidler-McKay P, et al.
Leukemia
. 2023 May;
37(6):1406.
PMID: 37157018
No abstract available.
9.
Li Z, Chang T, Junco J, Devidas M, Li Y, Yang W, et al.
Blood
. 2023 Mar;
142(2):172-184.
PMID: 37001051
Trisomy 21, the genetic cause of Down syndrome (DS), is the most common congenital chromosomal anomaly. It is associated with a 20-fold increased risk of acute lymphoblastic leukemia (ALL) during...
10.
Schore R, Angiolillo A, Kairalla J, Devidas M, Rabin K, Zweidler-McKay P, et al.
Leukemia
. 2023 Mar;
37(6):1375-1378.
PMID: 36966262
No abstract available.